Fundraising FoxHatch BioFund — Full Portfolio
7 tracked investments · listed companies and verified rows first
Ladder Bio (formerly ThirdLaw Molecular) develops Spiroligomer molecules, a class of synthetic, modular fused-ring compounds designed for highly selective binding to target proteins, along with computational design tools for targeted drug discovery.
BiotechDeep TechMedical DevicesBlue Bell, US
Christian Schafmeister(Founder)inEric Heil(Chief Executive Officer)in
Co-investorsMedical Excellence CapitalSmartGateVC
Latus develops gene therapy research and development capabilities leveraging cell and gene therapy expertise.
AI & Machine LearningBiotechDeep TechHealthtechPhiladelphia, US
Co-investors8VCBioAdvanceDCVC (Data Collective)DCVC BioGaingelsKorea Development Bank+1 more
__Twitter.png)
MasterSwitch Bio is developing master transcription therapy aimed at rescuing end-stage organs.
Biotech
Christina Galbraith(Chief Operating Officer)
Optimeos develops a nanoparticle-based drug formulation and delivery platform (CINCs and LINCs) for complex biologics including mRNA, DNA, peptides, and proteins, targeting rare diseases, immunology, and metabolic conditions such as obesity.
BiotechDeep TechHealthtechPrinceton, US
Robert K. Prud'homme, PhD(Director)Bob Prud'homme(Leadership (PhD))Rob Pagels(Leadership (PhD))Chet Markwalter(Leadership (PhD))inShahram Hejazi(Leadership (PhD))inGregory Harriman(Leadership (MD))in
Co-investors7G BioVenturesAnzu Partners
Vittoria develops immunotherapies, specifically CAR T-cell therapies, to treat difficult-to-treat diseases including cancers beyond B-cell types.
BiotechDeep TechMedical DevicesPhiladelphia, US
Nicholas Siciliano(Director)inPreston Noon(Executive Officer)
BoardGeeta Vemuri(Executive Officer, Director)Bruce Peacock(Executive Officer, Director)Leon Moulder(Director)
Co-investorsAgent CapitalBioAdvanceGlobal BioAccess Fund
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
HulaLadder Bio
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.